24 unknown, 15 recruiting, 7 not yet recruiting, 5 completed. 41 Phase 2, 7 Not applicable, 6 Phase 3, 2 Phase 1, 1 Phase 4.
Follow HAIC: new trials by email Literature Review of HAIC trials Research Report on HAIC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome Shuganhuazhuo Formula, Targeted therapy, Immunotherapy - HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine | Phase 2 | Not yet recruiting | Xiang-Qian | 120 | 2027-09-01 | 2026-08-27 |
| Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes Epalrestat, Donafenib + Tislelizumab, HAIC - HCC - Hepatocellular Carcinoma, Diabetes | Phase 2 | Not yet recruiting | Haibo Shao | 32 | 2026-10-01 | 2026-09-21 |
| A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion HAIC, Donafenib + lenvatinib+apatinib, Sintilimab+camrelizumab+tislelizumab - Liver Cancer | Phase 4 | Not yet recruiting | Zhai Wenlong | 40 | 2026-08-30 | 2026-08-27 |
| A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma Yttrium-90, HAIC - Hepatocellular Carcinoma (HCC) | Not applicable | Recruiting | Li Qiang | 286 | 2026-08-01 | 2025-08-27 |
| HAIC Plus QL1706 & Bevacizumab in Unresectable HER2-Negative ICC hepatic arterial infusion chemotherapy (HAIC) combine with QL1706 and bevacizumab - Intrahepatic Cholangiocarcinoma | Phase 2 | Recruiting | Lianghe Lu | 35 | 2026-06-11 | 2026-09-25 |
| HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion HAIC, Lenvatinib, PD-1 Inhibitors - Hepatocellular Carcinoma (HCC) | Active not recruiting | Peking University | 150 | 2026-05-29 | 2026-06-09 | |
| The DoHAICs Study Expansion Phase Donafenib, sintilimab, HAIC - HCC - Hepatocellular Carcinoma | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 90 | 2026-05-20 | 2026-05-13 |
| Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma FOLFOX regimen, Immunotherapy, targeted therapy - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | BinYong Liang | 100 | 2026-04-30 | 2026-04-13 |
| Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma Bevacizumab Biosimilar IBI305, ipilimumab N01, Sintilimab - HCC - Hepatocellular Carcinoma, Conversion Therapy | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 43 | 2026-03-30 | 2026-05-01 |
| TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma TACE, HAIC, PD-1inhibitors - HCC | Not yet recruiting | Tongji Hospital | 364 | 2026-01-31 | 2026-01-14 | |
| Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer HAIC, Gemcitabine plus Cisplatin, Adebrelimab - Biliary Tract Cancer | Phase 2 | Recruiting | Air Force Military Medical University, China | 124 | 2025-12-10 | 2026-05-06 |
| HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA) Camrelizumab, Rivoceranib (Apatinib), HAIC - Mixed Hepatocellular-cholangiocarcinoma | Phase 2 | Recruiting | Fudan University | 45 | 2025-08-15 | 2025-08-17 |
| Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma FOLFOX4, Adebrelimab, Apatinib - Hepatocellular Carcinoma(HCC) | Not applicable | Recruiting | Nanjing Tianyinshan Hospital | 270 | 2025-05-22 | 2026-10-01 |
| HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03) Sintilimab, Bevacizumab Biosimilar, HAIC - Hepatocellular Carcinoma (HCC) | Phase 2 | Recruiting | Fudan University | 164 | 2025-03-18 | 2026-04-21 |
| ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC Lenvatinib, Pembrolizumab, Atezolizumab - HCC - Hepatocellular Carcinoma | Phase 2 | Recruiting | Peking Union Medical College Hospital | 300 | 2025-02-19 | 2025-12-01 |
| HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC PD-L1 inhibitor, HAIC - ICC, Advanced Cancer | Phase 2 | Recruiting | Eastern Hepatobiliary Surgery Hospital | 50 | 2025-01-01 | 2026-01-23 |
| HAIC Compared With TACE in Huge Hepatocellular Carcinoma TACE, HAIC - Hepatocellular Carcinoma, Hepatic Chemotherapy | Recruiting | Sun Yat-sen University | 664 | 2024-10-01 | 2025-03-26 | |
| Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma hepatic artery infusion chemotherapy - Hepatocellular Carcinoma | Not applicable | Recruiting | RenJi Hospital | 1115 | 2024-08-01 | 2024-08-07 |
| Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma Donafenib, Sintilimab, HAIC - Hepatocellular Carcinoma | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2024-07-30 | 2024-07-22 |
| Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma HAIC, Lenvatinib plus pucotenlimab - Cholangiocarcinoma Non-resectable | Phase 2 | Recruiting | Tongji Hospital | 36 | 2024-06-04 | 2026-07-22 |
Showing 20 of 58. Sign in to see all of them.
Carcinoma, Hepatocellular (38) · Cholangiocarcinoma (6) · Liver Neoplasms (5) · Colorectal Neoplasms (3) · Carcinoma (2) · Biliary Tract Neoplasms (1) · Diabetes Mellitus (1) · Digestive System Neoplasms (1) · Gallbladder Neoplasms (1)
Tianjin Medical University Cancer Institute and Hospital (10) · Sun Yat-sen University (8) · Peking University (4) · Fudan University (3) · Peking University Cancer Hospital & Institute (3) · Lei ZHAO (2) · Tongji Hospital (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) · Wan-Guang Zhang (2) · Air Force Military Medical University, China (1) · BinYong Liang (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Eastern Hepatobiliary Surgery Hospital (1) · Haibo Shao (1) · Hui-Chuan Sun (1)
China (50)
Ming Shi, MD (2) · Xiaodong Wang, MD (2) · Baocai Xing, Doctor (1) · Feng Duan, MD (1) · Haibo Shao (1) · Hui-Chuan Sun, MD&PhD (1) · Jin Bo Yue, Dr. (1) · Kangshun Zhu, Dr. (1) · Lei Zhang, PHD (1) · Li Bing, PhD. (1) · Liyun Zheng, MD. (1) · Min-shan Chen, MD, PhD (1) · Tao Han (1) · Wan-guang Zhang, M.D. (1) · Wanguang Zhang (1)
PMID 40812353, PMID 11981766, PMID 12049862, PMID 12540794, PMID 19491285, PMID 20375404, PMID 20686792, PMID 20839057, PMID 21514523, PMID 25111859, PMID 25742141, PMID 25995680, PMID 26695839, PMID 27095655, PMID 28596308, PMID 30785198, PMID 31070690, PMID 32372672, PMID 35103539, PMID 36529949, PMID 40475000, PMID 41537370, PMID 9149014